5 Key Takeaways
-
1
The LUGANO trial evaluated DURAVYU (EYP-1901) against aflibercept in wet AMD but did not meet the primary endpoint for visual acuity.
-
2
Nine DURAVYU patients experienced ≥15-letter vision loss from causes unrelated to neovascular AMD, impacting trial results.
-
3
DURAVYU demonstrated strong anatomic control and reduced treatment burden, with 76% of patients remaining supplement-free at Week 32.
-
4
The trial showed a 42% reduction in treatment burden compared to aflibercept, indicating fewer required injections.
-
5
The next Phase 3 trial, LUCIA, is expected to provide further data, with results anticipated in Q4 2026.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
